Back to Search
Start Over
[Quality of Life Is Associated with Combined Lenalidomide and Dexamethasone Treatment in Japanese Patients with Relapsed or Refractory Multiple Myeloma].
- Source :
-
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2015 Dec; Vol. 42 (13), pp. 2461-6. - Publication Year :
- 2015
-
Abstract
- This study investigated the relationship between quality of life (QOL) and efficacy or occurrence of adverse events in patients who were administered lenalidomide and dexamethasone (Len+Dex) therapy for relapsed or refractory multiple myeloma (MM) in the hematology department at Obihiro Kosei Hospital from September 2010 to September 2012. QOL was evaluated using a quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD). The average QOL score of 7 patients receiving 4 cycles of Len+Dex treatment decreased 5 points from baseline Len+Dex treatment. The change in QOL score was significantly correlated with changes in serum M-protein (correlation coefficient: R=0.777). However, there was no significant correlation between adverse events and the change in QOL score. Our results indicate that QOL may be improved by the effects of Len+Dex treatment.
- Subjects :
- Aged
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Dexamethasone administration & dosage
Dexamethasone adverse effects
Female
Humans
Lenalidomide
Middle Aged
Surveys and Questionnaires
Thalidomide administration & dosage
Thalidomide adverse effects
Thalidomide analogs & derivatives
Antineoplastic Combined Chemotherapy Protocols adverse effects
Multiple Myeloma drug therapy
Quality of Life
Subjects
Details
- Language :
- Japanese
- ISSN :
- 0385-0684
- Volume :
- 42
- Issue :
- 13
- Database :
- MEDLINE
- Journal :
- Gan to kagaku ryoho. Cancer & chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 26809305